Brought to you by 
Public offering nets $37.6mm for Provention Bio
23 Sep 2019
Executive Summary
Provention Bio Inc. netted $37.6mm through a public offering of 5mm common shares at $8. The company is developing therapeutics for immune-mediated diseases and will use the proceeds to continue work on its pipeline projects for conditions including diabetes, inflammatory bowel disease, celiac disease, lupus, and acute coxsackie B virus. Concurrent with the public stock sale, Provention also announced that it received a $20mm private equity investment from strategic partner Amgen.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Public offering nets $37.6mm for Provention Bio
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice